Pd@Ir-LOD multienzyme utilizing endogenous lactate consumption cooperates with photothermal for tumor therapy

Ye, Zichen; Li, Yun; Li, Jingchao; Hu, Xinyan; Zheng, Jinyang; Gong-xin, Zhang; Xiang, Sijin; Zhu, Tianbao; Guo, Zhide; Chen, Xiaolan

doi:10.1007/s12274-023-5764-1

Cited by 2 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the therapeutic efficacy of LOX is limited by rapid clearance, easy degradation or inactivation, off-target effects, and toxicity. To improve the stability of LOX and its enrichment in tumor sites, some nanosized carriers, such as MOF, [94,97] cationic liposomes, [91,98] MSN, [99] hydrogel, [100] noble metal, [101] protein nanoparticles, [102] etc., have been developed for tumor-targeted delivery of LOX. Nevertheless, the catalytic efficiency of LOX is greatly limited by the insufficient supply of O 2 at tumor sites.…”

Section: Natural Biological Enzyme-based Nanosystemsmentioning

confidence: 99%

Current Advances on Nanomaterials Interfering with Lactate Metabolism for Tumor Therapy

Cheng,

Shi,

et al. 2023

Advanced Science

View full text Add to dashboard Cite

Increasing numbers of studies have shown that tumor cells prefer fermentative glycolysis over oxidative phosphorylation to provide a vast amount of energy for fast proliferation even under oxygen‐sufficient conditions. This metabolic alteration not only favors tumor cell progression and metastasis but also increases lactate accumulation in solid tumors. In addition to serving as a byproduct of glycolytic tumor cells, lactate also plays a central role in the construction of acidic and immunosuppressive tumor microenvironment, resulting in therapeutic tolerance. Recently, targeted drug delivery and inherent therapeutic properties of nanomaterials have attracted great attention, and research on modulating lactate metabolism based on nanomaterials to enhance antitumor therapy has exploded. In this review, the advanced tumor therapy strategies based on nanomaterials that interfere with lactate metabolism are discussed, including inhibiting lactate anabolism, promoting lactate catabolism, and disrupting the “lactate shuttle”. Furthermore, recent advances in combining lactate metabolism modulation with other therapies, including chemotherapy, immunotherapy, photothermal therapy, and reactive oxygen species‐related therapies, etc., which have achieved cooperatively enhanced therapeutic outcomes, are summarized. Finally, foreseeable challenges and prospective developments are also reviewed for the future development of this field.

show abstract